 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
17 July 2001 | Volume 135 Issue 2 | Pages 73-87
Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease.
Data Sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease.
Study Selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997.
Data Extraction: Data on 1860 nondiabetic patients were analyzed.
Data Synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% CI, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [CI, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [CI, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (CI, 0.51 to 0.94) for end-stage renal disease and 0.70 (CI, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d.
Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.
*For other members of the ACE Inhibition in Progressive Renal Disease Study Group, see Appendix 1.
Author and Article Information
From New England Medical Center, Tufts University School of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; University of Texas at Southwestern, Dallas, Texas; Institute di Recherche, Farmacologiche "Mario Negri," Bergamo, Ospedale Civile Maggiore, Verona, and Ospedale M. Malphigi, Bologna, Italy; Herlev Hospital, University of Copenhagen, Copenhagen, Denmark; The Royal Melbourne Hospital, Melbourne, and Royal Adelaide Hospital, Adelaide, Australia; Sahlgrenska University Hospital, Göteborg, Sweden; Hôpital Necker, Paris, France; Merck Research Laboratories, West Point, Pennsylvania; and University of Groningen, Groningen, the Netherlands.
Presented in abstract form at the 31st Annual Meeting of the American Society of Nephrology, 25 October 1998, Philadelphia, Pennsylvania; the 15th Congress of the International Society of Nephrology, 5 May 1999, Buenos Aires, Argentina; and the 32nd Annual Meeting of the American Society of Nephrology, 5 and 7 November 1999, Miami, Florida.
Grant Support: By grant RO1 DK53869A from the National Institute of Diabetes and Digestive and Kidney Diseases (Dr. Levey); grants RO1 HS08532 (Drs. Schmid and Lau) and RO1 HS 10064 (Dr. Schmid) from the Agency for Healthcare Research and Quality; grant 1097-5 from the Dialysis Clinic, Inc., Paul Teschan Research Fund (Dr. Jafar); New England Medical Center-St. Elizabeth's Hospital Medical Center Clinical Research Fellowship Program, Boston, Massachusetts (Dr. Jafar); and an unrestricted grant from Merck Research Laboratories, West Point, Pennsylvania (Dr. Levey).
Requests for Single Reprints: Andrew S. Levey, MD, Division of Nephrology, New England Medical Center, 750 Washington Street, Box 391, Boston, MA 02111.
Current Author Addresses: Dr. Jafar: Department of Medicine, The Aga Khan University, Stadium Road, PO Box 3500, Karachi, Pakistan.
Dr. Schmid: Division of Clinical Care Research, Biostatistics Research Center, New England Medical Center, Box 63, 750 Washington Street, Boston, MA 02111.
Ms. Landa: Division of Clinical Care Research, New England Medical Center, Box 63, 750 Washington Street, Boston, MA 02111.
Dr. Giatras: 50 G. Papandreou Street, Nea Erythrea, 14671 Athens, Greece.
Dr. Toto: Dallas Nephrology Associates, 6010 Forest Park Road, Suite 100, Dallas, TX 75235.
Dr. Remuzzi: Institute di Recherche, Farmacologiche "Mario Negri," Via Gavezzeni 11, 24125 Bergamo, Italy.
Dr. Maschio: Division Nefrologia, Ospedale Civile Maggiore, 37126 Verona, Italy.
Dr. Brenner: Renal Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02111.
Dr. Kamper: Department of Nephrology, Herlev Hospital, University of Copenhagen, DK 2730 Herlev, Denmark.
Dr. Zucchelli: Department of Nephrology, Ospedale M. Malphigi, Via P. Palagi 9, Bologna, Italy.
Dr. Becker: Department of Nephrology, The Royal Melbourne Hospital, Grattan Street, Melbourne, Victoria 3050, Australia.
Dr. Himmelmann: Department of Clinical Pharmacology, Sahlgrenska University Hospital, S41345 Göteborg, Sweden.
Dr. Bannister: Renal Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Dr. Landais: Service d'Informatique et de Statistiques Médicales, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France.
Dr. Shahinfar: Merck Research Laboratories, 10 Sentry Parkway, Walton and Stenton Avenue, BL-1, Blue Bell, PA 19422.
Drs. de Jong and de Zeeuw: University of Groningen, Oostersingel 59, 9713 EZ Groningen, the Netherlands.
Dr. Lau: Division of Clinical Care Research, New England Medical Center, Box 827, 750 Washington Street, Boston, MA 02111.
Dr. Levey: Division of Nephrology, New England Medical Center, 750 Washington Street, Box 391, Boston, MA 02111.
Author Contributions: Conception and design: C.H. Schmid, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey.
Analysis and interpretation of the data: T.H. Jafar, C.H. Schmid, M. Landa, J. Lau, A.S. Levey.
Drafting of the article: T.H. Jafar, C.H. Schmid, A.S. Levey.
Critical revision of the article for important intellectual content: T.H. Jafar, C.H. Schmid, M. Landa, R. Toto, P.E. de Jong, A.S. Levey.
Final approval of the article: T.H. Jafar, C.H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, J. Lau, A.S. Levey.
Provision of study materials or patients: R. Toto, G. Remuzzi, G. Maschio, B.M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P.E. de Jong, D. de Zeeuw, A.S. Levey.
Statistical expertise: C.H. Schmid, J. Lau.
Obtaining of funding: T.H. Jafar, C.H. Schmid, S. Shahinfar, J. Lau, A.S. Levey.
Administrative, technical, or logistic support: C.H. Schmid, M. Landa, A.S. Levey.
Collection and assembly of data: T.H. Jafar, M. Landa, I. Giatras, A.S. Levey. ARTICLE
Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
A Meta-Analysis of Patient-Level Data
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. B. Chapman Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney Disease: Insights from the CRISP and HALT-PKD Studies Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1197 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kohn Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease Evid. Based Med., June 1, 2008; 13(3): 73 - 73. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Shariff, M. S. Cuerden, A. K. Jain, and A. X. Garg The Secret of Immortal Time Bias in Epidemiologic Studies J. Am. Soc. Nephrol., May 1, 2008; 19(5): 841 - 843. [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Appel, J. T. Wright Jr, T. Greene, J. W. Kusek, J. B. Lewis, X. Wang, M. S. Lipkowitz, K. C. Norris, G. L. Bakris, M. Rahman, et al. Long-term Effects of Renin-Angiotensin System-Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans Arch Intern Med, April 28, 2008; 168(8): 832 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Izuhara, M. Nangaku, S. Takizawa, S. Takahashi, J. Shao, H. Oishi, H. Kobayashi, C. van Ypersele de Strihou, and T. Miyata A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models Nephrol. Dial. Transplant., February 1, 2008; 23(2): 497 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Knoll, M. Cantarovitch, E. Cole, J. Gill, S. Gourishankar, D. Holland, B. Kiberd, N. Muirhead, R. Prasad, L. A. Tibbles, et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design Nephrol. Dial. Transplant., January 1, 2008; 23(1): 354 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kunz, C. Friedrich, M. Wolbers, and J. F.E. Mann Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease Ann Intern Med, January 1, 2008; 148(1): 30 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van de Wal, P. van der Harst, W. B. Gerritsen, F. van der Horst, T. H. Plokker, R. T Gansevoort, W. H van Gilst, and A. A Voors Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 177 - 180. [Abstract] [PDF]
|
|
|
|
|
|
H. N. Reich, S. Troyanov, J. W. Scholey, D. C. Cattran, and for the Toronto Glomerulonephritis Registry Remission of Proteinuria Improves Prognosis in IgA Nephropathy J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3177 - 3183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ding, A. Zhang, S. Huang, X. Pan, G. Zhen, R. Chen, and T. Yang ANG II induces c-Jun NH2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1889 - F1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ardissino, S. Vigano, S. Testa, V. Dacco, F. Paglialonga, A. Leoni, M. Belingheri, L. Avolio, A. Ciofani, A. Claris-Appiani, et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy report from the ItalKid Project database Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2525 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Borer Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E2 - E9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kent, T. H. Jafar, R. A. Hayward, H. Tighiouart, M. Landa, P. de Jong, D. de Zeeuw, G. Remuzzi, A.-L. Kamper, A. S. Levey, et al. Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1959 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garcia-Garcia, G. Briseno-Renteria, V. H. Luquin-Arellan, Z. Gao, J. Gill, and M. Tonelli Survival among Patients with Kidney Failure in Jalisco, Mexico J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1922 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, R. Gong, A. Rifai, E. M. Tolbert, and L. D. Dworkin Long-Term, High-Dosage Candesartan Suppresses Inflammation and Injury in Chronic Kidney Disease: Nonhemodynamic Renal Protection J. Am. Soc. Nephrol., March 1, 2007; 18(3): 750 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-L. Kamper The importance of a correct evaluation of progression in studies on chronic kidney disease Nephrol. Dial. Transplant., January 1, 2007; 22(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, C. Pozzi, and S. Andrulli IgA nephritis: ACE inhibitors, steroids, both or neither? Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3357 - 3361. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Clase Glomerular filtration rate: Screening cannot be recommended on the basis of current knowledge BMJ, November 18, 2006; 333(7577): 1030 - 1031. [Full Text] [PDF]
|
|
|
|
|
|
M. Abbate, C. Zoja, and G. Remuzzi How Does Proteinuria Cause Progressive Renal Damage? J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2974 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfeffer and E. D. Frohlich Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M.A. van de Wal, R. T. Gansevoort, P. van der Harst, F. Boomsma, H.W. Thijs Plokker, D. J. van Veldhuisen, P. E. de Jong, W. H. van Gilst, and A. A. Voors Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients Hypertension, November 1, 2006; 48(5): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Clase and A. X Garg Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain Evid. Based Med., October 1, 2006; 11(5): 145 - 145. [Full Text] [PDF]
|
|
|
|
|
|
P. Rossing, H.-H. Parving, and D. de Zeeuw Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction? Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2354 - 2357. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Griffin and A. K. Bidani Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1054 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Hollenberg and M. Epstein Renin Angiotensin System Blockade and Nephropathy: Why Is It Being Called into Question, and Should It Be? Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1046 - 1048. [Full Text] [PDF]
|
|
|
|
|
|
N. Halbesma, D.-S. Kuiken, A. H. Brantsma, S. J.L. Bakker, J. F.M. Wetzels, D. De Zeeuw, P. E. De Jong, R. T. Gansevoort, and for the PREVEND Study Group Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2582 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jacobs Costs and benefits of improving renal failure treatment--where do we go? Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2049 - 2052. [Full Text] [PDF]
|
|
|
|
|
|
C. Jones, P. Roderick, S. Harris, and M. Rogerson Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2133 - 2143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kanno, T. Takenaka, T. Nakamura, and H. Suzuki Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 730 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. Clark, J. J. Macnab, S. J. Chen, R. Suri, L. Moist, and A. X. Garg Evaluation of GFR Estimating Equations in the General Community: Implications for Screening Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 787 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sandhu, N. Wiebe, L. F. Fried, and M. Tonelli Statins for Improving Renal Outcomes: A Meta-Analysis J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2006 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Teplitsky, Y Shoenfeld, and A Tanay The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans Lupus, June 1, 2006; 15(6): 319 - 325. [Abstract] [PDF]
|
|
|
|
 |
|
 M.S. MacGregor, D.E. Boag, and A. Innes Chronic kidney disease: evolving strategies for detection and management of impaired renal function QJM, June 1, 2006; 99(6): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S.M., M. T., S. A., Y. H.T., C. D., K. S.A., S. V.P., W. B., L. P.S., T. S.M., et al. Leaking Capillaries and White Lung in Sepsis--Is Angiopoietin 2 the Culprit?: Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans. PLoS Medicine 3: e46, 2006 J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1207 - 1217. [Full Text] [PDF]
|
|
|
|
|
|
T. Miyata and C. van Ypersele de Strihou Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering Nephrol. Dial. Transplant., April 1, 2006; 21(4): 846 - 849. [Full Text] [PDF]
|
|
|
|
|
|
M. Ravera, M. Re, L. Deferrari, S. Vettoretti, and G. Deferrari Importance of Blood Pressure Control in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S98 - S103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr., P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. A. Farber, et al. Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate Ann Intern Med, February 7, 2006; 144(3): 172 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Levey and K. Uhlig Which Antihypertensive Agents in Chronic Kidney Disease? Ann Intern Med, February 7, 2006; 144(3): 213 - 215. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kida Apolipoprotein E and Progression of Chronic Kidney Disease JAMA, January 4, 2006; 295(1): 35 - 35. [Full Text] [PDF]
|
|
|
|
|
|
K. D.C., L. D.F., W. J., H. D., Y. X, T. J., B. K., S. M., D. P., L. R., et al. Accessory Renal Arteries--Mostly, But Not Always, Innocuous: Renin-Dependent Hypertension Caused by Nonfocal Stenotic Aberrant Renal Arteries--Proof of a New Syndrome. Hypertension 46: 380-385, 2005 J. Am. Soc. Nephrol., January 1, 2006; 17(1): 3 - 11. [Full Text] [PDF]
|
|
|
|
|
|
Y. Izuhara, M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, C. van Ypersele de Strihou, and T. Miyata Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3631 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kida Target Blood Pressure and Kidney Disease Ann Intern Med, August 16, 2005; 143(4): 310 - 311. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Engel, H. Johnson, R. P. Baughman, and A. I. Richards High-Output Heart Failure Associated with Anagrelide Therapy for Essential Thrombocytosis Ann Intern Med, August 16, 2005; 143(4): 311 - 313. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Levey and C. D. Mulrow An Editorial Update: What Level of Blood Pressure Control in Chronic Kidney Disease? Ann Intern Med, July 5, 2005; 143(1): 79 - 81. [Full Text] [PDF]
|
|
|
|
|
|
A. Zhang, G. Ding, S. Huang, Y. Wu, X. Pan, X. Guan, R. Chen, and T. Yang c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1118 - F1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Jafar, C. H. Schmid, and A. S. Levey Serum Creatinine as Marker of Kidney Function in South Asians: A Study of Reduced GFR in Adults in Pakistan J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1413 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. X. Garg, M. Mamdani, D. N. Juurlink, C. van Walraven, and for the Network of Eastern Ontario Medical Laborat Identifying Individuals with a Reduced GFR Using Ambulatory Laboratory Database Surveillance J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W.R. Doulton, F. J. He, and G. A. MacGregor Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension Hypertension, May 1, 2005; 45(5): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, April 25, 2005; 165(8): 936 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Jacobsen Preventing end stage renal disease in diabetic patients -- genetic aspect (part I) Journal of Renin-Angiotensin-Aldosterone System, March 1, 2005; 6(1): 1 - 14. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Sarnak, T. Greene, X. Wang, G. Beck, J. W. Kusek, A. J. Collins, and A. S. Levey The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Ann Intern Med, March 1, 2005; 142(5): 342 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
Article
